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Abstract
Background: Extracellular vesicles are membrane vesicles that are released into the extracellular environment and
accumulate in the circulation in vascular disease. We aimed to quantify circulating extracellular vesicles in pregnant
women with type 1 diabetes and to examine associations between extracellular vesicle levels, continuous glucose
measures, and pregnancy outcomes.
Methods: We used plasma samples from the Continuous Glucose Monitoring in Women with Type 1 Diabetes in
Pregnancy Trial study and quantified circulating extracellular vesicles by flow cytometry (n = 163). Relationships with
clinical variables were assessed by repeated measures correlation. Logistic regression was used to assess
associations between elevated extracellular vesicle levels and pregnancy outcomes.
Results: Platelet extracellular vesicle levels were inversely associated with glucose time above range and glycaemic
variability measures (P < 0.05). A weak positive association was observed between endothelial extracellular vesicles
and mean amplitude of glycemic excursion (P < 0.05). In a univariate logistic regression model, high baseline
endothelial extracellular vesicles was associated with increased risk of neonatal intensive care unit (NICU) admission
(OR: 2.06, 1.03–4.10), and respiratory distress requiring ventilation (OR: 4.98, 1.04–23.92). After adjusting for HbA1c
and blood pressure the relationship for NICU admission persisted and an association with hyperbilirubinemia was
seen (OR: 2.56, 1.10–5.94). Elevated platelet extracellular vesicles were associated with an increased risk of NICU
admission (OR: 2.18, 1.04–4.57), and hyperbilirubinemia (OR: 2.61, 1.11–6.12) after adjusting for HbA1c and blood
pressure.
Conclusions: High levels of extracellular vesicles in early pregnancy were associated with adverse neonatal
outcomes. Assessment of extracellular vesicles may represent a novel approach to personalized care in type 1
diabetes pregnancy.
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Biomarker
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: d.feig@utoronto.ca; dburger@uottawa.ca
A complete list of members of the CONCEPTT Collaborative Group can be
found in the Supplementary Material.
7Department of Medicine, University of Toronto, Toronto, ON, Canada
1Chronic Disease Program, Kidney Research Centre, Ottawa Hospital Research
Institute, Ottawa, Canada
Full list of author information is available at the end of the article
Abolbaghaei et al. Biomarker Research            (2021) 9:67 
https://doi.org/10.1186/s40364-021-00322-8
Background
Maternal vascular health is a critical determinant of
pregnancy outcomes and endothelial injury/dysfunction
may play a causal role in acute and longer-term mater-
nal fetal health outcomes [1, 2]. Biomarkers of vascular
injury, for example, soluble intercellular adhesion
molecule-1 and soluble vascular cell adhesion molecule-
1 elevations, are associated with preterm delivery [3].
Similarly, an increase in serum levels of the anti-
angiogenic sFlt-1 is associated with a higher rates of
early and late preterm births, low birth weight and pre-
eclampsia [4]. Impairment in endothelial function
(assessed by flow-mediated dilatation) is observed in
women with preeclampsia as compared to women with-
out complications which highlights the important role of
the endothelium in disease pathogenesis [5, 6]. Given
the importance of the maternal vasculature to both ma-
ternal and fetal health, the assessment of maternal vas-
cular health may aid in identification of individuals at
greatest risk of complications and allow for intervention
with strategies to improve vascular health [7]. For ex-
ample, the use of real time continuous glucose monitor-
ing has been shown to improve maternal and neonatal
outcomes, however its effect on maternal vascular health
is not known.
One emerging approach for the assessment of vascular
health is enumeration of circulating extracellular vesicles
(EVs). EVs are membrane-enclosed vesicles lacking rep-
licative capacity that are released into the extracellular
environment and involved in cell signaling [8]. A sub-
class of large EVs (L-EVs) historically termed micropar-
ticles/microvesicles are ~ 100-1000nm in size and shed
from the surface of cellular membranes under stress
conditions [8, 9]. EVs are comprised of miRNA, mRNA
and membrane and cytosolic protein but generally lack
nuclear material [8]. EVs exist in numerous biological
fluids such as urine, blood plasma, ascites and sputum
[8, 9]. Circulating EVs have been extensively studied and
primarily originate from platelets, endothelial cells, and
leukocytes [10, 11]. Notably, levels of circulating endo-
thelial EVs demonstrate strong inverse correlations with
arterial flow-mediated dilatation, and positive correla-
tions with systolic blood pressure and pulse wave vel-
ocity [12, 13]. Elevated circulating endothelial EVs, as
assessed by flow cytometry, have been shown to predict
risk of adverse cardiovascular events independent of
traditional risk factors [14, 15].
In diabetes, studies have consistently observed elevated
levels of circulating EVs (particularly endothelial EVs)
among individuals with type 1 and type 2 diabetes [16,
17]. Sabatier and colleagues revealed that individuals
with type 1 diabetes have higher numbers of circulating
endothelial, platelet, and total annexin V–positive EVs
and increased EV procoagulant activity in comparison
with age-matched control subjects [17]. Similarly, Li, S.
et al. observed that platelet and monocyte EVs are ele-
vated in individuals with type 2 diabetes [18]. Improved
glycemia is associated with reduced levels of circulating
EVs in individuals with type 2 diabetes after bariatric
surgery [19]. Thus, assessment of EV levels may reflect
dynamic changes to the vasculature in diabetes.
To date, the predictive value of circulating EVs in
pregnancy is unclear. The aim of our study was to quan-
tify circulating EVs in pregnant women with type 1 dia-
betes and to examine the associations between EV levels
with glycaemia, blood pressure and pregnancy outcomes.
We hypothesized that levels of endothelial EVs would be
positively correlated with glucose levels and that high
levels would be associated with adverse pregnancy out-
comes. A secondary goal of this work was to determine
whether the use of real time continuous glucose moni-
toring alters levels of circulating EVs.
Methods
Study participants and ethics
We examined plasma samples from the Continuous Glucose
Monitoring in Pregnant Women with Type 1 Diabetes
(CONCEPTT) trial bioreposity [20]. Details of the clinical
study protocol have been previously published [20, 21]. In
brief, women with type 1 diabetes who were pregnant or
planning pregnancy were randomized to receive real-time
continuous glucose monitoring (CGM) or standard care.
Those receiving standard care wore a masked CGM at 4–12,
24 and 34 weeks gestation. We conducted a secondary ana-
lysis on biospecimens from all 163 pregnant participants with
at least one plasma sample available for analysis. Samples
from collections at 4–12 weeks (baseline), 24, and 34 weeks
gestation were studied. A summary of baseline characteristics
and pregnancy outcomes is shown in Table 1. The study was
approved by the Mount Sinai Research Ethics Board (ID#:
17-0066-E) and the Ottawa Hospital Research Ethics Board
(ID#: 20170658-01 H). Samples were analyzed in a blinded
fashion.
Continuous glucose monitoring metrics
Summary metrics for CGM measures were obtained for
baseline, 24, and 34 weeks gestation. Measures included
the mean CGM glucose level, the percentage of time spent
within the pregnancy glucose target range (TIR, 63–
140 mg/dL), and time spent above (TAR, > 140 mg/dL)
and below (TBR, 63 mg/dL) the target range, mean ampli-
tude of glycemia excursion (MAGE), and measures of gly-
cemic variability (SD and coefficient of variation [CV]).
Isolation and immunolabeling of EVs from archived
plasma
We isolated circulating L-EVs (often referred to as mi-
croparticles) from archived platelet-free plasma as
Abolbaghaei et al. Biomarker Research            (2021) 9:67 Page 2 of 10
described previously [22]. Plasma samples were thawed
quickly in a water bath at 37 °C. One hundred seventy-
five microliter of samples were centrifuged at 12,000 × g
for 2 min at 4 °C. One hundred fifty microliter of the
supernatant was transferred to fresh tubes and centri-
fuged at 20,000 x g for 20 min. The supernatant was dis-
carded and L-EV pellets were re-suspended in 150 µl of
Annexin V binding buffer (10mM HEPES 140 mM
NaCl, 2.5 mM CaCl2, pH 7.4). In fresh tubes, 30 µl of
the samples were diluted in Annexin V binding buffer to
a final volume of 200 µl for platelet labelling. The
platelet samples labelling was performed using anti-
CD41-APC (1:100) and Annexin V- FITC (1:50) as la-
bels. Endothelial/leukocytes labelling was conducted by
diluting 120 µl of resuspended samples in Annexin V
binding buffer to a final volume of 200 µl. Anti-CD144-
PE (1:100), anti-CD45-BV421 (1:25) and Annexin V-
FITC (1:50) were used to label endothelial/leukocytes
samples. After labeling, samples were re-centrifuged at
20,000 g x 20 min after a two hours incubation in the
dark. The supernatant was removed, and pellet was pre-
served and re-suspended in Annexin Binding Buffer (300
µL). The samples were transferred to flow cytometry
tubes for analysis. All isotype controls, antibodies and
Annexin V were purchased from BioLegend (San Diego,
USA).
Quantitation of circulating EVs by nanoscale flow
cytometry
L-EVs were quantified at the University of Ottawa Flow
Cytometry and Virometry Facility using a Beckman
Coulter CytoFLEX S with CyExpert Version 2.3.0.84.
ApogeeMix beads (Apogee Flow Systems, Hertfordshire,
UK) were used to establish a size gate of ~ 100–1000
nm. L-EVs were identified as ~ 100–1000 nm particles
in size staining positive for the membrane marker
Annexin V compared to negative controls. Results are
expressed as the number of annexinV+ (Total), annexin
V + and CD41+ (platelet), annexin V + and CD45+
(leukocyte) or annexin V + and CD144+ (endothelial)
EVs/ mL plasma. Samples labelled with isotype controls,
antibodies alone in buffer, and unlabelled samples were
analyzed as controls. FlowJo ver 7.6.5 was used for
analysis.
Statistical analysis
Direct comparisons between EV levels were conducted
by t-test or ANOVA (as appropriate) using GraphPad
Prism version 9 (GraphPad Software).
Univariate and multivariate logistic regression models
were tested using SPSS version 26 (IBM Corp, Armonk,
NY). Logistic regression models with baseline EV levels
as a dichotomous variable (above and below median
value) were used to evaluate relationships with maternal
and neonatal outcomes. Multivariate logistic regression
models were designed a priori to adjust for known risk
factors that have been shown to correlate with circulat-
ing EV levels in the general population (factors included
were: systolic and diastolic blood pressure and HbA1c%.)
Relationships between EV levels and continuous vari-
ables throughout the study were assessed by repeated
measures correlation in R 3.5.1 using the repeated mea-
sures correlation (rmcorr) package version 0.4.0 [23].
All graphs were constructed using GraphPad Prism. A
P value < 0.05 was considered significant.
Table 1 Baseline characteristics and pregnancy outcomes
Characteristica
Age- years 31.4 ± 4.8
BMI- kg/m² 25.7 ± 0.3
European/Mediterranean origin 141
(86.5 %)
Duration of diabetes- years 16.7 ± 7.9
Presence of diabetes complications 50 (30.7 %)
Nulliparity 66 (40.4 %)
Systolic blood pressure- mmHg 115.3 ±
16.1
Diastolic blood pressure- mmHg 69.8 ± 9.9
History of preeclampsia 10 (6 %)
Maternal outcome
Hypertension (Worsening Chronic, Gestational or Pre-
eclampsia)
37 (22.7 %)
Preeclampsia 20 (12.3 %)
Gestational Hypertension 15 (9.2 %)
New onset proteinuria 25 (15.3 %)
Episodes of severe hypoglycemia 4 (2.5 %)
Impaired liver function 15 (9.2 %)
Vaginal labour 54 (33.1 %)
Caesarean labour 104
(63.8 %)
Maternal complications 22 (13.5 %)
Maternal length of hospital stay- days 4.9 ± 3.5
Neonatal Outcome
Early preterm (< 34 weeks) 10 (6.3 %)
Late preterm (34–37 weeks) 53 (32.5 %)
Birthweight- g 3553 ± 737
Gestational age at delivery- weeks 37.0 ± 2.0
Neonatal length of hospital stay (days) 5.5 ± 5.8
Neonatal intensive care unit admission 52 (31.9 %)
Neonatal hypoglycaemia 35 (21.5 %)
Composite fetal outcome 70 (43 %)
Respiratory distress 11 (6.8 %)
Antenatal corticosteroids (y/n) 41 (25 %)
avalues are mean ± SD or n (%) as appropriate
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Results
EV levels throughout pregnancy
We first examined levels of circulating platelet, endothe-
lial, leukocyte, and total EVs to determine if levels
change throughout type 1 diabetes pregnancy. We did
not observe significant differences in levels of endothelial
(P = 0.43), leukocyte (P = 0.65), platelet (P = 0.82), or
total EVs (P = 0.58) between trimesters (Supplemental
Fig. 1).
Association between circulating EVs and glycemic
variables
We next analyzed relationships of EVs with HbA1c and
continuous glucose measures throughout pregnancy by
repeated measures correlation (Table 2). We did not ob-
serve significant associations between EV populations
and mean glucose (24 h, obtained from CGM data) or
HbA1c. A weak positive correlation between endothelial
EVs and MAGE was observed but this was not accom-
panied by associations with other glycemic variability
markers including CV and SD. Interestingly, we ob-
served an inverse relationship between platelet EV levels
and glucose SD, MAGE and TAR as well as a positive
correlation with TIR suggesting an inverse relationship
between platelet EVs and glucose levels. No relationships
between leukocyte EVs and HbA1c or continuous glu-
cose measures were observed.
We also examined the association between EV levels
and blood pressure by repeated measures correlation.
There was no correlation between endothelial or platelet
EVs with either systolic or diastolic blood pressure.
However, we did observe a positive correlation between
leukocyte EVs and both systolic and diastolic blood pres-
sure (Table 2).
Effect of CGM on circulating EV
We next assessed whether using CGM compared with
self-monitoring of blood glucose (SMBG) had an effect
on circulating EVs. Figure 1 shows the effect of use of
CGM on platelet, endothelial, leukocyte, and total EV
levels at 34 weeks gestation. No differences between
CGM and SMBG were observed for circulating endothe-
lial, platelet, leukocyte, or total EVs at 34 weeks
gestation.
EVs and pregnancy outcomes
Finally, given that EV levels are reflective of vascular
health, we assessed whether baseline levels of EVs were
predictive of pregnancy outcomes. In a univariate logis-
tic regression model, we observed that higher baseline
levels of endothelial EVs (above median) were associated
with increased risk of neonatal intensive care unit
(NICU) admission, respiratory distress requiring positive
pressure ventilation, and positivity for the composite
fetal outcome (an aggregate of pregnancy loss, birth in-
jury, neonatal hypoglycaemia, and respiratory distress)
[Fig. 2A]. After adjusting for HbA1c, systolic and dia-
stolic blood pressure, we observed significant positive as-
sociations with NICU admission, composite neonatal
outcome, and hyperbilirubinemia (Fig. 2B). A weak posi-
tive association between baseline endothelial EV levels
and maternal length of hospital stay was also observed
(p = 0.03, r = 0.17).
With respect to platelet EVs, we observed that low
levels of platelet EVs were associated with maternal
Table 2 Association between circulating endothelial EVs and
clinical variables by repeated measures correlation
EV population Clinical Variable r 95% CI p
Endothelial HbA1c 0.040 -0.072, 0.164 0.44
Mean CGM Glucose 0.091 -0.006, 0.186 0.06
% TIR (63-140mg/dl) -0.005 -0.129, 0.118 0.94
% TAR( >140mg/dl) 0.064 -0.060, 0.187 0.31
% TBR (<63mg/dl) -0.116 -0.236, 0.008 0.07
Glucose CV -0.012 -0.135, 0.112 0.85
Glucose SD 0.054 -0.070, 0.177 0.39
MAGE 0.129 0.005, 0.248 0.04
SBP 0.082 -0.035, 0.196 0.17
DBP 0.075 -0.043, 0.189 0.21
Platelet HbA1c 0.009 -0.107, 0.126 0.88
Mean CGM Glucose -0.111 -0.231, 0.013 0.08
% TIR (63-140mg/dl) 0.159 0.035, 0.276 0.01
% TAR( >140mg/dl) -0.138 -0.257, -0.014 0.03
% TBR (<63mg/dl) -0.055 -0.178, 0.068 0.38
Glucose CV -0.109 -0.229, 0.015 0.08
Glucose SD -0.147 -0.267, -0.025 0.02
MAGE -0.152 -0.271, -0.029 0.01
SBP 0.051 -0.066, 0.167 0.39
DBP 0.099 -0.017, 0.210 0.09
Leukocyte HbA1c 0.001 -0.116, 0.116 0.99
Mean CGM Glucose 0.003 -0.120, 0.127 0.95
% TIR (63-140mg/dl) 0.007 -0.116, 0.131 0.91
% TAR( >140mg/dl) 0.003 -0.121, 0.127 0.96
% TBR (<63mg/dl) -0.030 -0.154, 0.093 0.62
Glucose CV 0.008 -0.115, 0.132 0.89
Glucose SD 0.013 -0.110, 0.137 0.83
MAGE 0.001 -0.124, 0.123 0.99
SBP 0.179 0.064, 0.289 0.002
DBP 0.200 0.093, 0.315 0.001
Significant relationships are bolded
CGM continuous glucose monitoring, TIR time in range, TAR time above range,
TBR time below range, CV coefficient of variation, SD standard deviation, MAGE
mean amplitude of glycemic excursion, SBP systolic blood pressure, DBP
diastolic blood pressure
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complications in the unadjusted model (Fig. 3A). After
adjustment for baseline HbA1c and blood pressure,
platelet EVs were inversely associated with maternal
complications (Fig. 3B). By contrast positively associa-
tions with neonatal intensive care unit admission, hyper-
bilirubinemia, and composite fetal outcome (Fig. 3B).
We did not observe any relationships between leukocyte
EVs and pregnancy outcomes (data not shown).
Discussion
Our major finding is that baseline levels of circulating
EVs are higher in women with neonatal complications.
After adjustment for known risk factors (HbA1c and
blood pressure), higher baseline endothelial EVs were as-
sociated with increased NICU admission and hyperbilir-
ubinemia. Similarly, higher baseline platelet EVs were
associated with increased risk of NICU and hyperbiliru-
binemia but decreased maternal complications after ad-
justment for HbA1c and blood pressure.
It is well established that glucose is a potent stimulus
for EV formation. We have shown that high glucose in-
duces L-EV release from cultured endothelial cells [24]
and podocytes [25] and that acute hypoglycemia in-
creases urinary podocyte EV levels [26]. Similarly,
mesangial cells release more EVs in response to high
glucose stimulation [27] and animal and clinical studies
consistently show elevations in circulating EVs in dia-
betes [16–19]. Surprisingly, we did not observe any cor-
relation between circulating EVs and HbA1c or mean
glucose. We did observe a weak positive correlation be-
tween endothelial EVs and MAGE but other measures
of glucose variability (SD, CV) did not show the same re-
lationship. Similarly, we did not observe any associations
between endothelial EVs and blood pressure values.
Thus, while glucose and blood pressure may influence
endothelial EV levels in type 1 diabetes in pregnancy,
other factors are also contributing to EV dynamics. Per-
haps more surprising is the observation that platelet EVs
were inversely correlated with MAGE, SD, and time
above range and positively correlated with time in range.
These data suggest that platelet EV formation may be
reduced with hyperglycaemia in pregnancy and are in
contrast to studies outside of pregnancy including a sys-
tematic review which reported that platelet EVs are in-
creased in hyperglycaemic conditions [17, 18]. The
reason for this discrepancy is unclear although ours is
the first study to examine this relationship in type 1 dia-
betes in pregnancy. Two previous studies, performed
15–20 years ago in normal, hypertensive and growth re-
stricted pregnancies, reported reduced platelet EV levels
Fig. 1 The effect of RT-CGM on levels of circulating EVs. Shown are values of circulating levels of EVs at 34 weeks gestation in individuals utilizing
real time continuous glucose monitoring (CGM) compared with conventional self-monitoring of blood glucose (SMBG). A Platelet-derived EV; B.
Endothelial-derived EV; C. Leukocyte-derived EV and D. Total annexin + EVs. The number of participants for CGM and SMBG are n = 72 and n = 77
respectively. No significant differences were observed for platelet-derived EVs (0.74), endothelial-derived EV (0.88), leukocyte-derived EVs (0.31), or
total annexin V + EVs (0.17)
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in preeclampsia despite evidence of platelet activation
[28, 29] so it is possible that the molecular mechanisms
underlying platelet EV formation are altered in preg-
nancy. Further study is needed to better understand the
relationship between glucose levels and platelet EVs in
pregnancies complicated by diabetes.
The use of CGM in individuals with type 1 and type 2
diabetes is well established to improve glycemic control
and it has been speculated that the improved glycemia
associated with CGM, may reduce microvascular com-
plications [30–32]. Our laboratory and others have re-
ported that endothelial EVs are biomarkers of glucose-
induced endothelial injury [17, 24]. Given this, we hy-
pothesized that CGM, which was associated with im-
proved glucose levels in the randomized controlled trial
[20], would lead to reduced circulating endothelial EVs.
However, we did not observe any differences in circulat-
ing EVs between the SMBG control and CGM interven-
tion groups. Given the modest improvement in glucose
levels, this secondary analysis was likely not powered to
detect between-group differences in EVs. In addition,
the short duration of the intervention (started in the late
first/early second trimester) may not have been sufficient
to impact cellular injury and resultant EV formation.
Fig. 2 High baseline endothelial EV levels are associated with adverse pregnancy outcomes. A: Forest plot depicting the relationship between
baseline endothelial EV levels and pregnancy outcomes. B: Forest plot depicting the relationship between baseline endothelial EV levels and
pregnancy outcomes after adjusting for the HbA1c and systolic and diastolic blood pressure. Maternal complications indicates the presence of
oliguria, cerebral of visual symptoms, impairment of liver function, pulmonary edema or cyanosis, epigastric or right upper quadrant pain, or
thrombocytopenia. Composite Neonatal Outcome: aggregate measure of pregnancy loss, birth injury, neonatal hypoglycaemia, and respiratory
distress; LGA: Large for gestational age (> 90 percentile); Ventililation: respiratory distress requiring positive pressure ventilation
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Our most striking observation is that high levels of
endothelial and platelet EVs early in pregnancy were as-
sociated with adverse neonatal outcomes. Elevated levels
of EVs have long been known to predict adverse cardio-
vascular outcomes in other populations. Sinning et al.
[15] showed that high levels of endothelial EVs were as-
sociated with increased cardiovascular morbidity and
mortality over a 6 year follow-up. Similarly, Amabile
et al. revealed that endothelial EVs are elevated in indi-
viduals with pulmonary hypertension and directly linked
to hemodynamic severity of this condition [14]. In the
present study we found that high levels of endothelial
EVs (above median value) were associated with increased
NICU admission, neonatal respiratory distress requiring
positive pressure ventilation, and hyperbilirubinemia.
Similarly, high levels of platelet EVs, after adjustment for
HbA1c and blood pressure, were associated with NICU
admission, neonatal resuscitation, hyperbilirubinemia
and positivity for the composite fetal outcome. Curi-
ously, low levels of platelet EVs also seemed to predict
maternal complications in this cohort. Of note is the ob-
servation that high levels of EVs were not predictive of
preeclampsia in this population in contrast to other
studies which found that EVs were increased in pre-
eclampsia [33, 34]. This may be related to the sample
size, low number of cases in our study population and
differences between normal, hypertensive and diabetes
pregnancies.
Endothelial EVs are also engaged in pathological pro-
cesses as they are able to induce vascular injury [24, 35–
37]. Previous studies have shown that EVs induce endo-
thelial inflammation, haemostasis, angiogenesis, and
Fig. 3 Relationship between platelet EV level and pregnancy outcomes. A: Forest plot depicting the relationship between baseline platelet EV
levels and pregnancy outcomes. B: Forest plot depicting the relationship between baseline platelet EV levels and pregnancy outcomes after
adjusting for the baseline HbA1c and systolic and diastolic blood pressure
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endothelial dysfunction [35]. Thus, in addition to serving
as biomarkers of vascular injury they may actually in-
duce vascular dysfunction through direct actions on
endothelial cells leading to increased oxidative stress, in-
flammation, and impaired endothelium-dependent vaso-
relaxation [24, 36–40]. We and others have previously
shown that endothelial EVs exert greater deleterious ef-
fects on the endothelium when formed under hypergly-
caemic conditions [24, 41]. Bidirectional EV-mediated
cross-talk between the maternal vasculature and pla-
centa may also play an important role in disease patho-
genesis. In this regard, Kohli et al. have shown that
maternal EVs can promote inflammatory responses in
trophoblasts [42] and Han et al. recently reported that
placental-derived EVs can induce preeclamptic symp-
toms in mice [43]. Whether this is true in diabetes preg-
nancy and whether increased EVs played a causal role in
the pregnancy-related complications observed in the
present study is a subject for future investigation.
One of the strengths of this study is the use of human
plasma samples from a multicenter, randomized con-
trolled trial with extensive participant characterization.
In addition, while many studies focus on a single EV
population, our flow cytometry approach examined EVs
from endothelial cells, leukocytes, and platelets. Indeed,
we were able to identify predictive value for both endo-
thelial and platelet EVs. In addition, the availability of
CGM data allowed for assessment of relationships be-
tween EVs and glycaemia to an extent that has not been
done previously. Nevertheless, our study also has limita-
tions: First, while this represents a large cohort in the
context of prior work, it is still a relatively small sample
with limited neonatal complications. Second, relation-
ships between EV levels were assessed at only three time
points and this may have limited our ability to identify
associations with clinical variables. Finally, our cohort
was a secondary analysis of a clinical trial focused exclu-
sively on pregnant women with type 1 diabetes. As such
we were unable to compare values to those without dia-
betes or those with type 2 or gestational diabetes. Given
differences in sample collection methods, interlaboratory
differences in sample preparation, analysis, and instru-
ment sensitivity numeric comparisons to previous data
is challenging, however we note that the levels of endo-
thelial and platelet EVs seen in our study are slightly
higher than previous reports in non-pregnant healthy
donors, individuals with type 1 or type 2 diabetes or in
non-diabetic pregnant individuals [16, 17, 44]. However
direct comparison may not be appropriate as these dif-
ferences could be due to greater assay sensitivity.
Conclusions
In summary, our results suggest that elevated endothelial
or platelet EVs are associated with perinatal
complications in pregnant women with type 1 diabetes.
Accordingly, assessment of EV levels early in pregnancy
may aid in identifying women at high risk of neonatal
complications.
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